Top Markets
#1 BCGame Coin BCGame Coin +5.93%
#2 Tornado Cash Tornado Cash +5.13%
#3 Fake World Assets Fake World Assets +3.87%
#4 StonkBroker StonkBroker +2.14%
#5 Osmosis Osmosis +2.14%
#6 AtomOne AtomOne +2.05%
#7 aPriori aPriori +1.76%
#8 Nockchain Nockchain +1.73%
#9 Ether.fi Ether.fi +1.62%
#10 BORA BORA +1.46%
Coin of the day
BCGame Coin BCGame Coin
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Vicapsys Life Sciences, Inc. Vicapsys Life Sciences, Inc.

Vicapsys Life Sciences, Inc.

VICP
Rang in Aktien #25718
Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive... Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive VICAPSYN product to market, guiding it through development and commercialization. This product's intended application is within the field of transplantation, specifically for various transplant therapies and associated stem-cell uses. Additionally, the company is advancing the development of VYBRIN, a compound based on CXCL12. VYBRIN is being investigated for multiple purposes: preventing the formation of post-surgical adhesions following abdominal operations, coating implantable medical devices and other implants to inhibit fibrosis, and promoting wound healing, with a particular emphasis on diabetic ulcers. The firm, originally incorporated in 1997, transitioned its name from Phage Therapeutics International, Inc. to Vicapsys Life Sciences, Inc. in September 2017. Its operations are headquartered in Suwanee, Georgia.
Aktienkurs
$1.45
Zuletzt synchronisiert: 2026-08-19
Marktkapitalisierung
$46.94M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-18.08%
Land
US
Handel Vicapsys Life Sciences, Inc. (VICP)

Kategorie

Healthcare
P/S-Verhältnis für Vicapsys Life Sciences, Inc. (VICP)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Vicapsys Life Sciences, Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für Vicapsys Life Sciences, Inc. von 2026 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US